HNWAG
SYRE icon

High Net Worth Advisory Group’s Spyre Therapeutics SYRE Stock Holding History

High Net Worth Advisory Group’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$303K Buy
+6,000
New +$226K 0.07% 194

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

High Net Worth Advisory Group's SYRE Position: Q1 2026 in Review

High Net Worth Advisory Group opened a new position in Spyre Therapeutics (SYRE) in Q1 2026: 6,000 shares worth $303K. The stake represents 0.07% of the portfolio and ranks #194 among its holdings.

197 funds tracked by Wall St. Rank hold SYRE as of Q1 2026.

  • High Net Worth Advisory Group held 6,000 shares of Spyre Therapeutics worth $303K as of Q1 2026.
  • Spyre Therapeutics was a new High Net Worth Advisory Group position in Q1 2026.
  • Spyre Therapeutics made up 0.07% of High Net Worth Advisory Group's portfolio in Q1 2026, its #194 holding.
  • 197 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2026.

Based on High Net Worth Advisory Group's 13F filing for Q1 2026, filed 17 Apr 2026.